ABC | Volume 111, Nº6, December 2018

Viewpoint Helal et al Sudden death in young athletes Arq Bras Cardiol. 2018; 111(6):856-859 This is an open-access article distributed under the terms of the Creative Commons Attribution License 13. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002;359(9309):881-4. 14. Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA. Cost- effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. Ann Intern Med. 2010;152(5):276-86. 15. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41(6):974-80. 16. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-92. 17. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-55. 18. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. 19. Kelly BS, Mattu A, Brady WJ. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am J Emerg Med. 2007;25(1):72-9. 20. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. 21. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96. 22. Olesen J, Ringholm S, Nielsen MM, Brandt CT, Pedersen JT, Halling JF, et al. Role of PGC-1alpha in exercise training- and resveratrol-induced prevention of age-associated inflammation. Exp Gerontol. 2013;48(11):1274-84. 23. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077-109. 24. GarfinkelAC,SeidmanJG,SeidmanCE.GeneticPathogenesisofHypertrophic and Dilated Cardiomyopathy. Heart Fail Clin. 2018;14(2):139-46. 25. Fernandez-Falgueras A, Sarquella-Brugada G, Brugada J, Brugada R, CampuzanoO. Cardiac channelopathies and sudden death: recent clinical and genetic advances. Biology (Basel). 2017;6(1).pii:E7. 26. Crotti L, Kotta MC. The role of genetics in primary ventricular fibrillation, inheritedchannelopathiesandcardiomyopathies.IntJCardiol.2017;237:45-8. 27. Ewald IP, Cossio SL, Palmero EI, Pinheiro M, Nascimento IL, Machado TM, et al. BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. Genet Mol Biol. 2016;39(2):223-31. 28. Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A cost- effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2012;98(8):625-30. 29. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996;276(3):199-204. 30. Higgins JP, Andino A. Soccer and sudden cardiac death in young competitive athletes: a review. J Sports Med (Hindawi Publ Corp). 2013;2013:967183. 31. Maron BJ, Gohman TE, Kyle SB, Estes NA 3rd, Link MS. Clinical profile and spectrum of commotio cordis. JAMA. 2002;287(9):1142-6. 859